Indication
Treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.
Medicine details
- Medicine name:
- lutetium (177Lu) vipivotide tetraxetan (Pluvicto)
- SMC ID:
- SMC2517
- Pharmaceutical company
- Advanced Accelerator Applications
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC